Jane Street Group LLC Sells 328,208 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Jane Street Group LLC lowered its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 42.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 446,185 shares of the biopharmaceutical company’s stock after selling 328,208 shares during the period. Jane Street Group LLC owned about 0.34% of Dynavax Technologies worth $4,971,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC raised its position in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE raised its position in shares of Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies in the third quarter worth approximately $45,000. Nisa Investment Advisors LLC boosted its holdings in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the last quarter. Finally, Centiva Capital LP acquired a new stake in Dynavax Technologies during the 3rd quarter valued at approximately $119,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.85 on Tuesday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.01. The company has a fifty day moving average of $12.02 and a 200-day moving average of $11.48. The firm has a market capitalization of $1.69 billion, a P/E ratio of 98.85 and a beta of 1.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.